Serelaxin regulatory update

FDA rescheduled for March 27 a meeting of its Cardiovascular and Renal Drugs Advisory Committee to discuss a BLA from Novartis for serelaxin to treat acute heart failure (AHF). The meeting was originally scheduled for Feb. 13, but was postponed due to weather. The recombinant human relaxin 2 (RLN; H2) has FDA breakthrough therapy designation for the indication. ...